BioPorto

Remuneration Information • Apr 3, 2017

According to the company's guidelines relating to incentive remuneration and
the existing authorization in Section 18 of the Articles of Association, the
Board of Directors of BioPorto A/S ("BioPorto") (Nasdaq: BIOPOR) has decided to
issue new warrants to BioPorto’s management and certain employees. A total of
4,350,000 warrants are issued. Because of the program's accounting impact, the
EBIT forecast for the year 2017 is adjusted as further described below.

After the issuance of these warrants, the number of issued and not canceled
warrants amounts to 7,500,000.

The issuance of new warrants will support the company's long-term goals and
establish a performance-based remuneration reflecting the company's and
shareholders' interests.

Each warrant grants the holder the right to subscribe for one share in the
company. The exercise price is fixed at DKK 2.41 per share. Warrants will be
exercisable from January 1, 2019 until December 31, 2022. Within the exercise
period, warrants can be exercised within ordinary trading windows.

Conditions for cancellation of all warrants apply in case the company does not
achieve FDA approval of The NGAL Test™ before December 31, 2018. The program
also includes conditions on claw-back in case of erroneous financial
information and on accelerated vesting in case of e.g. takeover bid, resolution
and business transfer.

Detailed terms of the warrants are to be found in the Articles of Association
on www.bioporto.com under Investor Relations> Governance> Company Articles.

The total number of shares that participants will be able to subscribe upon
exercise of the warrants, are 4,350,000. The theoretical market value of the
allocations of warrants amounts to DKK 2,681,340, of which DKK 1,037,562
relates to the financial year 2017. The statement is based on the Black-Scholes
formula using an interest rate of -0.577% and the historical volatility of
BioPorto A/S' shares of 24 months calculated to 71.5%. An assumption regarding
the expected likelihood of vesting is set at two-thirds for the part of the
program that is associated with conditions for cancellation.

Adjustment of earnings expectations

As a result of the program's accounting impact, the EBIT forecast for the year
2017 is adjusted: From a negative EBIT of around DKK 25-28 million, as
announced in the annual report for 2016, to a negative EBIT of around DKK 26-29
million. The warrant program has no impact on cash flow.

For further information, please contact:

Thomas Magnussen, Chairman of the Board

Gry Husby Larsen, General Counsel

Telephone +45 4529 0000, e-mail investor@bioporto.com

About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides
healthcare professionals in clinical and research settings a range of
diagnostic tests and antibodies. Our pioneering product portfolio includes
assays for underserved disease states such as NGAL for acute kidney injury.
BioPorto has its headquarters in Copenhagen, Denmark and is listed on the
Nasdaq Copenhagen stock exchange.